Cailianshe (Shenzhen, reporter Zhou Xiaoya) reported that as the black swan event continues to ferment, it took only 10 trading days for international medicine to go from a potential stock that is about to accumulate strength to a ST stock that is about to become a star-stage stock.
htmlOn January 14, International Medicine announcement showed that since the opening of the market on January 17, 2022, the company's stock has been subject to other risk warnings. The stock abbreviation has changed from "International Medicine" to "ST National Medicine", and the stock trading day limit is 5%.According to the disclosed data, a total of 22 products hold the shares, and the shareholding ratio of A shares in circulation is 6.9%. Some funds under well-known fund managers such as Qiu Jingmin and Zhao Bei are among them.
As international medicine is about to "wear a hat", are these funds trapped or have they adjusted their positions? GF Fund today released an announcement on the adjustment of the international medical valuation held by its funds, and the valuation price was adjusted to 7.11 yuan.
22 funds hold international medical
Since the fourth quarter report of 2021 has not been disclosed, the holdings of of various public funds at the end of last year cannot be known. However, judging from the disclosed third-quarter report data, as of the end of the third quarter, 22 funds held International Medicine, involving 9 public funds, with a total of 132 million shares, accounting for 6.95% of the outstanding shares.
Among them, GF Growth Selection and GF Jufeng, a subsidiary of GF Fund, are ranked 4th and 6th largest circulating shareholders of the stock respectively. The fund managers of these two products are Qiu Jingmin.
As the hit "Sunlight Foundation" last year, GF Growth Selection started subscribing on January 18, 2021. The upper limit of the fundraising scale is 12 billion yuan, and the fundraising scale is completed in just one day, with the first fundraising scale exceeding 15 billion yuan.
Fund manager Qiu Jingmin said that he is a top student in medicine and is a bachelor's and doctoral student who jointly recruited Peking University and Peking Union Medical College . Due to solid research on the pharmaceutical industry, he mainly uses medicine, consumption, technology and high-end manufacturing in fund management.
was established in GF Growth Selection and entered the position building period , Qiu Jingmin was about to acquire International Medicine. As of the end of the first quarter, the stock entered the 8th largest holding stock of GF Growth Selection, with a holding of 23 million shares; in the following two quarters, GF Growth Selection continued to increase its holdings of the stock. As of the end of the third quarter, the stock was still the 8th largest holding stock, but the number of holdings increased to 30 million shares.
In fact, as early as the end of 2020, Qiu Jingmin had already taken a fancy to the stock. As of the end of 2020, GF Jufeng, who he was in charge, held 26 million shares of International Medicine, and was among the top ten heavily held stocks in the fund.
However, unlike GF Growth Select’s continuous increase in holdings, Qiu Jingmin reduced his holdings in International Medicine several times at GF Jufeng. As of the end of the third quarter of 2021, International Medicine has withdrawn from GF Jufeng's top ten heavily held stocks, with a holding of 15 million shares.
In addition to the above two funds, GF Advantage Growth managed by Qiu Jingmin also holds the stock. As of the end of the third quarter of last year, the number of shares held was 10 million.
Another well-known fund manager, Zhao Bei, managed by ICBC-RBC- Frontier Medical, became the fifth largest circulating shareholder of International Medicine at the end of last year's third quarter, with a shareholding of 15 million shares. However, the stock was not included in the top ten heavily held stocks of ICBC Credit Suisse Frontier Medical.
In addition, Huabao CSI Medical ETF is the 9th largest circulating shareholder of the stock and Bank of China Select is the 10th largest circulating shareholder of the stock.
Are funds trapped?
As international medicine is about to be ST, the flow of institutional funds, including these 22 public funds, has attracted much attention from the market.
html data on January 13 showed that institutional funds sold international medicine on a large scale. The data on the dragon and tiger list on the same day showed that among the top five seats sold, 4 were dedicated to institutions, with a total of about 200 million yuan.Since the beginning of the year, the cumulative net outflow of institutional funds in international medicine has exceeded 1.4 billion yuan.
Although, the first quarter report of last year was not fully disclosed, it is impossible to know the latest holdings of the above funds. However, GF Fund issued an announcement on the adjustment of the valuation of international medicine held by its funds today, revalued the valuation of international medicine held by its funds, and adjusted the valuation price to 7.11 yuan.
ICBC Frontier Medical's net value estimate on January 14 is -0.15%, but the fund has a valuation deviation of about 0.23%. This also means that the fund's holdings may have been adjusted.
International Medicine's " Black Swan "
On January 14, International Medicine has suspended trading of
. On the previous trading day, the stock closed at 8.37 yuan per share, and since the beginning of the year, the stock has fallen by 24.12%. In terms of the stretch cycle, the stock price has halved from the high of 21.66 yuan last year, with a pullback of more than 60%, with a total market value of 19 billion yuan.On January 13, International Medicine's "Announcement on the handling of subordinate hospitals from the Xi'an Municipal Health Commission" found the answer.
International Medicine stated that the company's Xi'an High-tech Hospital and Xi'an International Medical Center Hospital received the "Notice of the Xi'an Municipal Health Commission on the Handling of Xi'an High-tech Hospital and Xi'an International Medical Center Hospital" on the same day.
Xi'an Health Commission stated that after this round of epidemic, Xi'an Hi-Tech Hospital and Xi'an International Medical Center Hospital mechanically implemented relevant epidemic prevention policies in advance, delaying the rescue and diagnosis and treatment of critically ill patients, which aroused widespread public attention and caused serious consequences.
After research by the Xi'an Municipal Health Commission, the above two hospitals were ordered to suspend business and rectify for three months; and a warning was given; the hospital leaders were held accountable, including the general manager, deputy director in charge, head nurse in the outpatient department, etc., and the hospital's legal representative, chairman, outpatient department director, obstetrics department director, deputy director of the medical department, etc.
In addition, the Xi'an Municipal Health Commission criticized the incident across the city, summoned the main person in charge of the hospital, and instructed the hospital to do a good job in comforting the family.
In response to this, International Medicine expressed that it felt extremely sad, guilty and self-blame. It expressed its deep apology to the patients involved and their families and the public. It will do its best to handle the postoperative rehabilitation treatment, comfort and compensation of the patients involved and their families, and will reflect deeply, make immediate rectification, learn lessons, and hold the relevant responsible persons accountable.
The two aforementioned hospitals will also be closed for rectification from now on, and will properly handle patient guidance, employee training, internal rectification and other related work under the guidance of the provincial and municipal health committees. Resolutely prevent any such incidents from happening.
International Medicine further stated that the suspension of business rectification is expected to have a significant impact on the company's operating performance in 2022. According to relevant regulations, one trading day will be suspended on January 14, 2022, and other risk warnings will be implemented from the date of resuming trading.
"The company will strive to take various measures to strive to meet the requirement of revoking other risk warnings as soon as possible. After the corresponding circumstances are eliminated, the company will promptly announce and apply to the Shenzhen Stock Exchange to revoke other risk warnings." International Medicine stated that it will promptly fulfill its disclosure obligations based on the subsequent progress of the suspension and rectification. Investors are kindly requested to invest rationally and pay attention to risks. The delayed emergency treatment and treatment of patients mentioned in the announcement of
is the number of refusals that have been circulated at the beginning of the year before.
According to previous media reports, due to the nucleic acid expiration for 4 hours, a pregnant woman in Xi'an was unable to enter Xi'an Hi-Tech Hospital. She waited at the entrance of the hospital for 2 hours before a miscarriage. Another Xi'an netizen posted that his father had sudden angina pectoris and the High-tech International Medical Center refused to receive treatment on the grounds of medium-risk areas. In the end, his father died of delaying the thrombolysis time.
As a large domestic listed medical service group, International Medicine's overall revenue in 2020 was 1.607 billion yuan, while the revenue of the above two hospitals was 799 million yuan and 721 million yuan respectively, with the total revenue of the two being 1.52 billion yuan, accounting for 94.59% of the overall revenue.
